Opioid Stewardship and Chronic Pain

A GUIDE FOR PRIMARY CARE PROVIDERS
Managing chronic non-cancer pain

If opioid medication is part of the treatment plan, take the following steps:

>>> INFORMED CONSENT OR PAIN AGREEMENT: at least annually

>>> PRESCRIPTION DRUG MONITORING PROGRAM: check CURES every 4 months

>>> ASSESSMENTS OF RISK, FUNCTION AND PAIN: at least annually

>>> PRESCRIBE NALOXONE: every two years

If managing opioid use disorder, options include:

>>> Prescribe buprenorphine

>>> Arrange for methadone maintenance or extended-release naltrexone

>>> Arrange for residential or outpatient treatment
Chronic pain is defined as pain that lasts >3 months

According to a 2012 CDC survey, an estimated **126 million adults** reported some type of pain in the prior 3 months\(^1\)

In 2012, health care providers wrote **259 million opioid prescriptions**\(^2\)

In 2014, **10.3 million persons** reported using prescription opioids non-medically\(^3\)
Overdose is the leading cause of injury-related death in the US

INJURY-RELATED MORTALITY, 2015

- **Firearms (2014)**: 33,599
- **Motor vehicles**: 35,092
- **All poisonings**: 52,404

OPIOID OVERDOSE
Approximately half of opioid overdose deaths were from diverted opioids.

PRESCRIPTION VS. HEROIN OVERDOSE DEATHS

- **Opioid Pain Relievers**
- **Heroin**

FOR EVERY ONE PRESCRIPTION OPIOID OVERDOSE DEATH, THERE ARE:

- Treatment admissions for opioid use disorder: 10
- Emergency department visits for problems with use: 32
- People who use opioids non-medically: 825
Opioid overdose deaths in California

AGE-ADJUSTED RATE PER 100,000 RESIDENTS BY COUNTY, 2014

- >25
- 20-24.9
- 15-19.9
- 10-14.9
- 5-9.9
- 0-4.9
Accidental opioid overdose is preventable

Prior opioid overdose is a major risk for subsequent overdose and overdose death. A patient who has previously overdosed is 6 times more likely to overdose in the subsequent year.\textsuperscript{10}

**OTHER FACTORS THAT INCREASE RISK OF OVERDOSE:**

- Reduced tolerance: period of abstinence, change in dose, release from prison
- Genetic predisposition
- Concomitant use of substances: benzodiazepines, alcohol, cocaine

The majority of opioid overdose deaths involve at least one other drug, including benzodiazepines, cocaine or alcohol.\textsuperscript{8}
Informed consent
Informed consent and pain agreements

- **Informed Consent** is a joint discussion between provider and patient, documented in the chart, addressing risks associated with opioids and clarifying expectations.

- **Pain agreements** are written documents, similar to and possibly replacing informed consent, that address risks of opioid therapies, as well as expectations of both the patient and provider. Pain agreements are generally signed by the patient and renewed annually.

At a minimum, providers should offer written information to patients about the benefits and risks of opioid therapy and document patients’ understanding and agreement when initiating long-term opioid therapy and at least annually thereafter.

**CONTROLLED SUBSTANCE PATIENT-PROVIDER AGREEMENT**

The use of opioid pain medication is only one part of treatment for chronic pain.

The goals for using this medicine are:
- To improve my ability to work or function at home.
- To help my problem as much as possible.

<table>
<thead>
<tr>
<th>Provider’s Responsibilities</th>
<th>Patient Responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>__________________________</td>
<td>_________________________</td>
</tr>
</tbody>
</table>

Refills

| __________________________|
| __________________________|

Privacy

Prescriptions from Other Providers

Stopping the Medication

I have been told about the possible risks and benefits of this medicine.

<table>
<thead>
<tr>
<th>Patient’s name and signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>__________________________</td>
<td>______</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Provider’s name and signature</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>____________________________</td>
<td>______</td>
</tr>
</tbody>
</table>
What to include in a pain agreement

**ESSENTIAL**
- Reason for treatment
- Potential benefits and risks
- Assessments
- Expectations for future visits
- Discontinuation plan

**OPTIONAL**
- Additional elements of treatment plan (medication, other non-opioid treatments, physical therapy, etc.)
- Therapeutic goals, including physical ability, social function, dosing, duration
- Requirements for external consultation

**Additional considerations**
- Remind patients to keep opioids in locked and safe place.
- Encourage safe disposal of drugs, like take-back programs.
Starting opioid therapy

CDC recommends

Consider using episodic short-acting opioids and keeping at lowest effective dose.

Exercise caution:
- Doses ≥ 50 MME
- Concurrent use of benzodiazepine, alcohol or methadone for pain

Avoid if possible:
- Dose ≥ 90 MME

Inheriting patients already on opioid therapy can be complex
- Discuss with former provider
- Complete baseline assessments
- Establish expectations
- Engage in opioid use disorder treatment if appropriate

67% of those prescribed opioids for 90 days are still using opioids at 2 years.11
Tapering or discontinuing opioids

WHEN TO TAPER:
• When risks outweigh benefits

Consider tapering when opioid dose >90 MME or patient also takes benzodiazepines.

HOW TO TAPER:
• 1 medication at a time
• Tapers usually involve a monthly reduction of 10% of original dose
• Tapers may be as rapid as 50% in situations such as a low original dose or life-threatening adverse events

Consider a partial taper or transition to buprenorphine for some patients, particularly those on years of opioid therapy.

“I am more alert since I stopped taking [opioids] and I need less sleep, which is a blessing. So I’m able to do more things with my life.” —Patient on opioids for pain

Patient engagement
• Individualize the plan and be prepared to adjust
• Work with patient to set realistic goals
• Remind patient that reducing opioid use may reduce sensitivity to pain
• Encourage patient to engage support networks
• Use motivational interviewing techniques

Go to this link for a CDC patient toolkit on tapering: tinyurl.com/hfr7drd
Pain and function assessments

Assessments should focus on both pain and function.

- Assessments are essential when initiating opioid treatment or seeing a new patient already on long-term opioid therapy.
- Reassessments should take place at regular intervals to ensure benefit and evaluate adverse events.

TOOLS

- There are several tools for assessing pain and function, such as the Brief Pain Inventory or Initial Pain Assessment Tool.

ONE SIMPLE TOOL IS THE PEG—A 3 QUESTION SCALE

1. What number best describes your pain on average in the past week:

<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>No pain</td>
<td>Pain as bad as you can imagine</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

2. What number best describes how, during the past week, pain has interfered with your enjoyment of life?

<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does not interfere</td>
<td>Completely interferes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3. What number best describes how, during the past week, pain has interfered with your general activity?

<table>
<thead>
<tr>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
<th>5</th>
<th>6</th>
<th>7</th>
<th>8</th>
<th>9</th>
<th>10</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does not interfere</td>
<td>Completely interferes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The PEG is as valid and reliable as the longer Brief Pain Inventory and is sensitive to changes in pain. PEG can be found online at: tinyurl.com/hfdvzm3
Risk factor assessment

Asking simple questions like:

“How many times in the past year have you used an illegal drug or used a prescription medication for non-medical reasons?”

in a primary care setting (with an answer of one or more considered positive) was 100% sensitive and 73.5% specific in detecting a substance use disorder compared with a standardized diagnostic screening.

More formal assessments are available, such as the Opioid Risk Tool to measure patients’ potential risk with opioids, although evidence does not support their ability to accurately predict risk.

<table>
<thead>
<tr>
<th>Opioid Risk Tool</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mark each box that applies</td>
</tr>
<tr>
<td><strong>Family history of substance abuse</strong></td>
</tr>
<tr>
<td>Alcohol</td>
</tr>
<tr>
<td>Illegal drugs</td>
</tr>
<tr>
<td>Rx drugs</td>
</tr>
<tr>
<td><strong>Personal history of substance abuse</strong></td>
</tr>
<tr>
<td>Alcohol</td>
</tr>
<tr>
<td>Illegal drugs</td>
</tr>
<tr>
<td>Rx drugs</td>
</tr>
<tr>
<td>Age between 16—45 years</td>
</tr>
<tr>
<td>History of preadolescent sexual abuse</td>
</tr>
<tr>
<td>Psychological disease</td>
</tr>
<tr>
<td>ADD, OCD, bipolar, schizophrenia</td>
</tr>
<tr>
<td>Depression</td>
</tr>
<tr>
<td>Scoring totals</td>
</tr>
</tbody>
</table>
Urine drug screening

Urine drug screening can be used to check for substances that are expected and not expected to be present. This can help guide an informed discussion with patients about their medications.

- **Urine drug screening should NOT be used as a punitive tool,** rather it should be used like hemoglobin a1c, as a guide to ensure optimal care.

**CONTACT YOUR LAB FOR ASSISTANCE INTERPRETING URINE DRUG SCREENING RESULTS**

- **Not all assays test for all substances.** Opioids like methadone, fentanyl and buprenorphine may not appear on all tests.

- **Some opioids may be metabolites of opioids a patient is prescribed.** For example, the presence of hydromorphone in the urine of a patient prescribed morphine may be due to metabolism rather than use of non-prescribed opioids.

**OPIOID METABOLIC PATHWAYS**

![Diagram of opioid metabolic pathways]

- Morphine → Heroin → Codeine
- Codeine → Hydromorphone
- Morphine → Hydrocodone
- Oxycodone → Oxymorphone

**CDC recommends**

Conduct urine drug screening at first opioid prescription and at least annually thereafter.
Prescription Drug Monitoring Programs (CURES)

California’s Prescription Drug Monitoring Program (CURES: Controlled Substances Utilization Review and Evaluation System) is an online system used by prescribers to review prescriptions for controlled substances.

- **As of January 2016, CURES registration is mandatory** for all California licensed prescribers and pharmacists who are authorized to prescribe scheduled drugs.

- **As of 2017, California law (SB482) requires checking CURES** when starting opioid prescribing and re-checking **every 4 months**.

High quality prescription drug monitoring programs with mandated use may be associated with reduced opioid prescribing\(^\text{14}\) and modest reductions in opioid analgesic deaths.\(^\text{15}\)

CURES is updated weekly, although some prescriptions may not appear for weeks to months. Prescriptions from the VA and opioid use disorder treatment programs (such as methadone maintenance) are not included.
How to use CURES

HOW TO APPLY

• Use this link: oag.ca.gov/cures
• Click on the registration link on right panel.
• Follow instructions.

Record your password and security questions to simplify password reset.

FEATURES OF CURES

• Save search list: Save patient searches so they are easily available next time you log in.
• Peer-to-peer communication: Send notes, emails and alerts to providers/pharmacists about mutual patients.
• Alerts/messaging: Receive daily alerts with information on patients who reach prescribing thresholds.

CURES alerts prescribers to patients with multiple prescribers, high-dose opioids prescriptions, concomitant opioids and benzodiazapines and daily opioids over 90 days.
Naloxone

NALOXONE MECHANISM OF ACTION

- Highly specific, high-affinity opioid antagonist used to reverse the effects of opioids
- Lasts 30-90 minutes
- Can be administered by laypeople
- Virtually no side effects or effects in the absence of opioids

PROVIDING NALOXONE TO PEOPLE WHO USE DRUGS IS COST-EFFECTIVE

Cost: $421 per quality-adjusted life-year gained

Benefit:

164 naloxone scripts = 1 prevented death

Emerging data suggests that providing naloxone may encourage patients to be safer with their opioid use. If this is the case, the intervention would be cost-saving and 36 prescriptions would prevent one death.
Naloxone is effective

NALOXONE IS ASSOCIATED WITH REDUCED OVERDOSE MORTALITY

FATAL OPIOID OVERDOSE RATES BY NALOXONE IMPLEMENTATION IN MASSACHUSETTS

In California, counties with naloxone programs had an overall slower rate in the growth in opioid overdose deaths compared to counties without naloxone programs.

NALOXONE MAY REDUCE OPIOID RELATED ADVERSE EVENTS

OPIOID RELATED EMERGENCY DEPARTMENT VISITS BY RECIPIENT OF NALOXONE PRESCRIPTION AMONG PRIMARY CARE PATIENTS ON OPIOID THERAPY FOR CHRONIC PAIN

Prescribing naloxone to 29 patients averted 1 opioid-related emergency department visit in the following year.

*In a population with a rate of opioid-related emergency department visits of 7/1000 person years.
State law encourages naloxone prescribing

Naloxone is NOT a controlled substance. **Any licensed healthcare prescriber can prescribe naloxone.** California law provides additional protections to encourage naloxone prescribing and distribution.

**PROVIDER AND PATIENT PROTECTIONS (CA AB635)**

- **Providers are encouraged to prescribe naloxone** to patients receiving a long-term opioid prescription.

- **Naloxone prescriptions also can be written directly to third party individuals** (caregivers, family members, friends, etc.) who are in a position to witness and assist a person at risk of an opioid overdose.

- **A licensed healthcare prescriber can issue a standing order** for the dispensing of naloxone by healthcare or community workers to individuals at risk of experiencing or witnessing an overdose.

- **Laypeople can possess and administer naloxone** to others during an overdose situation.

**GOOD SAMARITAN PROTECTIONS (CA AB472)**

- **Witnesses of an overdose who seek medical help are provided legal protection from arrest and prosecution for minor drug and alcohol violations.**

**PHARMACIST PROVISION OF NALOXONE (CA AB1535)**

- **Pharmacists are allowed to directly prescribe and dispense naloxone to patients at risk of experiencing or witnessing an opioid overdose.**
COMMUNICATING WITH PATIENTS ABOUT NALOXONE

The word “overdose” may have negative connotations and prescription opioid users may not relate to it.

Some patients have overdosed and don’t realize it.

Out of 60 patients on opioid therapy for pain, 22 (37%) had stopped breathing or required help to be woken up due to opioids.20

Instead of using the word “overdose,” consider language like “accidental overdose,” “bad reaction” or “opioid safety.” You may want to say:

“Opioids can sometimes slow or even stop your breathing.”

“Naloxone is the antidote to opioids—it can be used if there is a bad reaction where you can’t be woken up.”

“Naloxone is for opioid medication like an epinephrine pen is for someone with an allergy.”

“Naloxone is important to have in the home in case someone is accidentally exposed to opioid painkillers.”

45% of these patients denied overdosing, calling it a bad reaction
Indications for naloxone prescribing

“By being able to offer something concrete [naloxone] to protect patients from the danger of overdose, I am given an opening to discuss the potential harms of opioids in a non-judgmental way.”
—Primary care provider

Consider naloxone for patients:

• With past or current illicit opioid use
• At risk of witnessing an opioid overdose

**CDC recommends**

• On prescribed opioids with:
  — Opioid use ≥50 MMEs/day
  — Benzodiazepine use
  — History of substance use disorder
  — History of opioid overdose

“I have never really thought about [overdose] before...[naloxone] was more so an eye opener for me to just look at my medications and actually start reading [about] the side effects, you know, and how long should I take them...I look at different options, especially at my age.”
—Patient on opioids for pain
Prescribing naloxone

Formulations

INTRANASAL (NARCAN)
- Naloxone 2mg or 4mg #1 two pack, use PRN for suspected opioid overdose

AUTO-INJECTOR
- Naloxone auto-injector 2mg #1 two pack, use PRN for suspected opioid overdose

Devices designed for lay use can cut down on patient education. If the above devices are not optimal, prescriptions can be written for the following formulations and education should be provided directly to the patient.

INTRANASAL
- Naloxone 2mg/2ml prefilled syringe #2, spray ½ into each nostril, use PRN for suspected overdose. Repeat if necessary.

(Note: Nasal atomizer generally not available through pharmacies.)

INJECTABLE
- Naloxone 0.4mg IM #2, use PRN for suspected overdose, IM syringe (3ml 25g 1” syringe) #2

SBIRT CODES COVER TRAINING
(per 15 min intervals)

<table>
<thead>
<tr>
<th></th>
<th>MediCare:</th>
<th>MediCal:</th>
<th>Commercial:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>G0396</td>
<td>H0050</td>
<td>CPT99408</td>
</tr>
</tbody>
</table>
Opioid use disorder
Managing opioid use disorder

- If your patient has an opioid use disorder, it is essential to arrange for treatment.
- Treatment with medications has the best evidence for managing opioid use disorder and should be considered for all patients with significant disease.
- When therapy for opioid use disorder is stopped, the risk of death increases.

FDA-APPROVED MEDICATION TREATMENT OPTIONS

- Buprenorphine
- Methadone
- Extended-release naltrexone

Like treatment for other chronic diseases such as diabetes, these medications should be considered long-term therapy.

BEHAVIORAL/PSYCHOLOGICAL TREATMENT OPTIONS

- Support groups such as Narcotics Anonymous
- Outpatient or inpatient rehabilitation and counseling

If not personally providing the treatment, a warm handoff to other providers is critical.
**Buprenorphine**

**SAFETY PROFILE**
- Due to the “ceiling effect” of a partial agonist, buprenorphine has:
  - Low potential for misuse and diversion
  - Low risk of respiratory depression or overdose
- Maintenance is critical: opioid use disorder requires long-term care.
- Buprenorphine treatment is safe and effective during pregnancy.
- Most buprenorphine for opioid use disorder treatment is co-formulated with naloxone to discourage diversion or injection of the product.

_BUPRENORPHINE_
- A partial opioid agonist
- Lasts 36 hours
- Has very high affinity, blocking effects of heroin or other opioids
Buprenorphine is an effective medication to treat opioid use disorder in primary care

ROUTINE MEDICATION MANAGEMENT CAN BE AS EFFECTIVE AS COMBINING BUPRENORPHINE WITH COUNSELING

While counseling should be sought if available, lack of access should not be a barrier to treatment.²²

PATIENTS CAN BE STARTED ON BUPRENORPHINE IN THE OFFICE OR AT HOME

Opioid use patterns are similar if patients start therapy themselves at home.²³

In a randomized controlled trial of buprenorphine, patients who used only prescription opioids responded even better than those who used heroin (P<0.001).²⁴
Buprenorphine reduces mortality and pain

**BUPRENORPHINE REDUCES MORTALITY, POSSIBLY EVEN MORE THAN METHADONE**

<table>
<thead>
<tr>
<th></th>
<th>METHADONE CMR (95%CI)</th>
<th>BUPRENORPHINE CMR (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>FIRST 4 WEEKS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>9.6 (6.5–13.5)</td>
<td>4.3 (2.0–8.2)</td>
</tr>
<tr>
<td>Drug related mortality</td>
<td>5.4 (3.2–8.5)</td>
<td>1.0 (0.1–3.4)</td>
</tr>
<tr>
<td><strong>REMAINDER OF TREATMENT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All-cause mortality</td>
<td>6.8 (6.3–7.4)</td>
<td>3.9 (3.1–4.9)</td>
</tr>
<tr>
<td>Drug related mortality</td>
<td>1.7 (1.4–2.0)</td>
<td>1.5 (1.0–2.1)</td>
</tr>
</tbody>
</table>

CMR = Crude Mortality Rate per 1,000 person years

**STUDIES SUPPORT USE OF BUPRENORPHINE FOR CHRONIC PAIN**

In a study of 35 patients on 200–1,370 morphine equivalent milligrams of opioids for chronic pain, after two months of sublingual buprenorphine:

- Pain scores reduced from 7.2 to 3.5 (p<0.001)
- Quality of life scores increased from 6.1 to 7.1 (p=0.005)
Prescribing buprenorphine as maintenance treatment for opioid use disorder requires an “X” number

• **An “X” number is a separate DEA registration number** that must be used when buprenorphine is prescribed for opioid use disorder.

• After getting an “X” number, you can prescribe ≤ 30 patients in year 1 and ≤ 100 patients in subsequent years.*

### To obtain an “X” number:

**IF YOU ARE A LICENSED MD OR DO:**

- Complete a free online training (or have substance use disorder treatment experience).

- Complete and submit a physician waiver.

**IF YOU ARE A LICENSED NP OR PA:**

- Complete the same online training as above.

- Complete a one-day training allowing treatment of up to 30 patients at one time.

- Complete and submit a waiver.

**YOU WILL RECEIVE A SECOND DEA REGISTRATION CARD WITH YOUR “X” NUMBER.**

Prescribing buprenorphine **ONLY** for pain does **NOT** require an “X” number, but may require prior authorization.

*MDs and DOs can apply to treat ≤ 275 patients after treating 100 for a year.
How to prescribe buprenorphine

FOR OPIOID USE DISORDER:
- No prior authorization necessary for MediCal
- Many patients stabilize around 16 mg (initial dose is generally 4-8 mg)
- Medication is generally administered sublingually and daily

FOR PAIN:
- Any formulation can be used, including the transdermal patch
- Prior authorization may be required
- No “X” number required
- Medication is generally administered 2-3 times daily

Formulations

STANDARD FOR OPIOID USE DISORDER:
- Coformulated buprenorphine/naloxone SL tab
- Coformulated buprenorphine/naloxone film or implant

IF PATIENT DOES NOT TOLERATE/CANNOT ACCESS COFORMULATED PRODUCTS:
- Monoformulated buprenorphine SL tablets

IF TREATING PAIN, MAY ALSO CONSIDER:
- Monoformulated buprenorphine transdermal patch
References

About this publication

This publication was produced by the San Francisco Department of Public Health (SFDPH) and funded by the California Department of Public Health (CDPH), supported by Grant Number 6NU17 CE002747 from the Centers for Disease Control and Prevention. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the Centers for Disease Control and Prevention, the Department of Health and Human Services, CDPH, or SFDPH. No pharmaceutical company resources were used in the development of these materials. The authors (Phillip Coffin, MD, MIA, and Emily Behar, MS) deny any financial conflicts of interest; Dr. Coffin has directed studies that received donated medications from Alkermes (2014–2015) and Gilead (2016–2017).

The recommendations contained in this brochure are general and informational only; specific clinical decisions should be made by providers on an individual case basis.